Business Context and Reporting Period
Endovia Health Sciences, Inc. (NYSE American: SBEV) filed a Form 8-K on August 20, 2026, reporting the entry into material definitive employment agreements. The filing details the appointment of Brady Cobb as Interim Chief Executive Officer and Michael Bondurant as Interim Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation terms.
Material Changes and Compensation Structure
The primary material change is the establishment of new executive compensation packages effective August 20, 2026:
- Base Salaries: Brady Cobb ($300,000 annually) and Michael Bondurant ($275,000 annually).
- Market Capitalization Bonuses:
- $50,000 cash bonus per executive if market cap increases by $5,000,000 above the agreement date level by October 30, 2026.
- $50,000 cash bonus per executive if market cap increases by $10,000,000 above the agreement date level by December 31, 2026.
- 3% of additional market cap above the $10,000,000 threshold achieved in 2026, capped at $300,000 aggregate per executive.
- Equity Grants:
- Brady Cobb: 231,250 stock options.
- Michael Bondurant: 200,000 stock options.
- Restricted Stock Units (RSUs): Subject to shareholder approval, each executive is entitled to 7% of the 20% of fully diluted shares approved by the Board.
- Acceleration Clauses: Unvested options and RSUs vest immediately upon termination without cause or a change of control.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, revenue outlook, or management commentary on operational performance. The compensation structure introduces a risk of significant dilution and cash outflow contingent on the company achieving specific market capitalization milestones within the 2026 calendar year. Annual performance bonuses based on revenue and profit targets are mentioned but specific goals are not disclosed.
Investor Verification Checklist
- Verify the Company's market capitalization as of August 20, 2026, to calculate the specific stock price targets required to trigger the $50,000 bonuses.
- Confirm the status of the shareholder vote required to approve the RSU grants.
- Review the full text of Exhibits 10.1 and 10.2 for detailed vesting schedules and termination provisions.
- Assess the potential dilution impact of the option grants and pending RSU allocations on existing shareholders.